

UNiTY



The newsletter of the Global Lung Cancer Coalition

Spring/Summer 25

03 Our latest global patient experience survey reveals encouraging trends

05 An overview of our new members from India and Hong Kong

06 Merrel Hennink from Longkanker Nederland talks patient involvement

10 Top tips on how to assess your presence on social media platforms

WELCOME

In 2001, nine organisations with an interest in lung cancer came together and formed the Global Lung Cancer Coalition.

Today, the GLCC is comprised of 43 non-government patient organisations from around the world.

Our aim is to increase awareness of lung cancer issues, change perceptions of lung cancer, help people with lung cancer access the information and support they need, and push governments and legislative bodies to improve treatment and care.

Already, we have achieved a lot. But we also know that much more must be done to improve the outcomes and lives of people affected by lung cancer – something we are determined to do.



To join us, please read our membership criteria, and download a membership application form at lungcancercoalition.org

GLCC PUBLISHES POSITION STATEMENT ON GLOBAL RESEARCH



The GLCC has developed a 'position document' outlining key actions that national governments should prioritise to strengthen the future of lung cancer research.

Since 2015, the GLCC has collaborated with the Institute for Cancer Policy (ICP) to assess the global landscape of lung cancer research.

Over the past decade, lung cancer research has seen a welcome increase, particularly in comparison to breast and bowel cancer. Notably, there has been a surge in studies focused on immuno-oncology treatments, now the leading area of lung cancer research. Encouragingly, international collaboration in this field has also grown.

However, significant research activity has been limited to just 24 countries. China and the United States dominate the field, with China alone accounting for nearly 36% of global lung cancer research papers by 2021.

While there are encouraging signs in the data, the ICP's findings highlight the urgent need for increased investment, greater diversity and stronger international collaboration in lung cancer research to improve future treatment and care.




Please click here to read the position statement in full.



GOOGLE TRANSLATE

Articles marked **Google Translate** have been translated from a non-English news story. This means you may need to paste the story into Google Translate and select your appropriate language.

TWO MORE FACTSHEETS NOW AVAILABLE



The GLCC added two more factsheets – Neoadjuvant and adjuvant treatments for non-small cell lung cancer and Pulmonary (lung) nodules – to the resources section of our website.

At present, the factsheets are only available in English, but we intend to translate these resources into other languages in the near future.

They are free to use, but, as ever, we ask that you credit the GLCC wherever possible.



Please click on the factsheets' names to access the appropriate one for your country:
[Neoadjuvant and adjuvant treatments for non-small cell lung cancer](#) and [Pulmonary \(lung\) nodules](#).



Please [click here](#) to view all the GLCC's factsheets.

GLCC BRIEFING ON RESEARCH IN EU NATIONS



The GLCC published in November 2024 a briefing document on the state of research in leading lung cancer research nations in the European Union.

These countries are namely: Austria, Belgium, Denmark, France, Germany, Greece, Italy, the Netherlands, Poland, Spain and Sweden.

The briefing paper draws on research carried out by the Institute for Cancer Policy (ICP) in 2023 to help produce the GLCC's State of Global Lung Cancer Research 2014–2021 report.

Key findings highlighted in the new briefing paper include:

Modest growth since 2014

The number of papers published on lung cancer across leading EU research countries stagnated from 2014–2019. However, in 2020 and 2021, there was a significant rise in papers published, resulting in a trajectory of modest growth in lung cancer research between 2014 and 2021.

Consistent focus

The focus of EU research remained relatively consistent between the periods 2004–2013 and 2014–2021. Discovery science, biomarker

research and drug research dominated the focus of lung cancer research during both periods, while palliative care remained under researched.

Greater collaboration

There is clear evidence that international collaboration has become more prevalent across Europe. Between 2014–17 and 2018–21 the percentage of research completed with international collaboration increased in every leading EU research country.

In preparing this briefing paper, the GLCC would like to express gratitude to the ICP for their valuable work and insightful findings.

The GLCC recognises the fundamental value of research in improving the lives of patients with lung cancer and calls on all countries to protect and invest in lung cancer research.



Please [click here](#) to read the full briefing document.



Please [click here](#) to read the State of Global Lung Cancer Research 2014–2021 report.

LATEST PATIENT EXPERIENCE SURVEY REVEALS ENCOURAGING TRENDS



The 2024 survey revealed some encouraging trends. These include greater involvement scores in treatment and care decisions compared to 2023, and improved support for patients who either opted out of treatment or had no available treatment options.

However, it was also clear from the survey results that more needs to be done to ensure patients get the information they need at the time that is most useful to them.

This is true across the patient journey. For example, 40% of respondents to the survey didn't know what was meant by 'biomarker testing' when they first heard about it. And 32% did their own research to understand what biomarker testing was.

A reminder to members that all the findings from the GLCC's fifth annual global patient experience survey are available on our [website](#).

You can download global findings in a PDF or Word document format, and an Excel spreadsheet outlining questions and patients' responses.

National infographics can also be downloaded for the following countries: Argentina, Australia, Bulgaria, Canada, Denmark, Greece, Ireland, Israel, Italy, Japan, Mexico, Portugal, South Africa, Spain, Taiwan, UK and USA.

TEMPLATE PRESS RELEASE FOR PATIENT SURVEY

The GLCC has produced a template press release to support members using data and country infographics from the fifth annual global patient experience survey.



Please click here to download the press release as a Word document.

CELEBRATE YOUR LUNG CANCER HEROES

Each member of the GLCC is encouraged to nominate a recipient for our Journalism or Special Recognition Awards for excellence in raising awareness of lung cancer.

The Journalism Award is not just for people working in traditional media such as press, radio and television. You can also nominate people who produce content for social media, news blogs, podcasts and other digital platforms.

The Special Recognition Award was created to celebrate the outstanding efforts of individuals or groups who go above and beyond to significantly raise awareness of lung cancer and issues surrounding the illness.



In 2024, Pulmonale of Portugal presented a Special Recognition Award to the MUCHE creative agency. This recognised the team's superb work

to promote lung cancer screening to people in Portugal and improve awareness of lung cancer and the outcomes of people diagnosed with it.

Isabel Maria Magalhães, President of Pulmonale, said, "This award is a well-deserved recognition of MUCHE's exceptional work in promoting and raising awareness of the implementation of lung cancer screening in Portugal, which has been instrumental in giving a voice to this cause."



To nominate a recipient for the Journalism or Special Recognition Award, please contact glcc@roycastle.org



NEWS FROM THE LUNG CANCER POLICY NETWORK



**LUNG CANCER
POLICY NETWORK**

As a member of the Lung Cancer Policy Network, the GLCC is pleased to present the latest news from the organisation.

SCREENING RECOMMENDATIONS FOR CENTRAL AND EASTERN EUROPE



Following an in-person roundtable, the Lung Cancer Policy Network has published a set of key recommendations for implementing low-dose computed tomography (LDCT) screening in Central and Eastern Europe.

The key recommendation for policymakers is to build on the updated screening recommendations published by the European Commission in 2022 and, where LDCT screening programmes have not been established, recognise their efficacy and develop a clear roadmap to implementation.

Recommendations for stakeholders involved in screening across Central and Eastern Europe include:

- Seek governmental policy engagement in order to build support for lung cancer screening.
- Share knowledge and best practice from existing screening programmes to optimise the development and implementation of new ones.
- Aggregate and analyse existing screening data to demonstrate LDCT screening's efficacy to policymakers.
- Involve general practitioners in the design, implementation and evaluation of a lung cancer screening programme to promote uptake and increase screening implementation success.

The Network hopes these discussions will act as a starting point for further collaboration and help to promote the implementation of screening across the region to improve survival from lung cancer.



Please click here to read the full recommendations for Central and Eastern Europe.

SCREENING RECOMMENDATIONS FOR ASIA-PACIFIC

The Lung Cancer Policy Network has published a set of recommendations for advancing lung cancer screening efforts in the Asia-Pacific region.

This followed a collaborative workshop with the Asia Pacific Coalition Against Lung Cancer at the Asia Conference on Lung Cancer in Hong Kong.

The recommendations for Asia-Pacific are:

- Improve awareness of lung cancer – and the importance of earlier detection – among policymakers, decision makers and the public.
- Foster collaboration and shared learning across multi-stakeholder groups, bringing together policymakers, advocates and data from existing pilots and programmes to support policymakers in prioritising lung cancer.
- Initiate local research on the effectiveness and cost-effectiveness of screening to inform decision-making.
- Take a systems approach to large-scale screening implementation, using data and lessons, to ensure that gaps in capacity are identified and addressed.

The LPCN is hopeful these recommendations will drive lung cancer screening efforts throughout the region.



Please click here to read the full recommendations for Asia-Pacific.

A REVIEW OF 2024

The Lung Cancer Policy Network (LCPN) has published *2024 in review: from evidence to action*.

Over the past year, the Network expanded to over 80 members from 34 countries, strengthening its role as a trusted voice.

Through advocacy activities, the LCPN raised awareness of key lung cancer issues and used evidence to shape meaningful policy recommendations.



Please click here to read about the Network in 2024 and its plans for 2025.



TWO NEW ORGANISATIONS JOIN THE GLCC

We are delighted to welcome two new organisations to the GLCC family: **Lung Connect India Foundation**, which is based in Mumbai, and **Cancer Information Network**, which is based in Hong Kong.



LUNG CONNECT INDIA FOUNDATION



**LUNG
CONNECT**

A FORUM FOR PATIENTS & CAREGIVERS

Lung Connect believes that knowledge is power. By providing comprehensive educational resources, we aim to empower patients and their families with the information they need to make informed decisions

about their health and treatment options. Our advocacy efforts focus on raising awareness, influencing policy changes, and ensuring that lung cancer patients receive the best possible care and support.

Our community is the heart of Lung Connect. We offer a supportive environment where individuals can connect, share experiences, and find strength in one another.


Through our programs and services, we strive to make the lung cancer journey more manageable and less isolating.

Lung cancer carries a heavy stigma, often unfairly associated solely with smoking. We address this issue by promoting a more compassionate and informed perspective. We conduct educational campaigns to highlight the various causes of lung cancer beyond smoking. By sharing patient stories that challenge the smoking stereotype and fostering support groups that welcome everyone regardless of background, we create a more inclusive and understanding community.

Additionally, our advocacy for research into non-smoking causes of lung cancer emphasizes the importance of broader awareness and earlier detection strategies for all individuals facing this disease. Join us in supporting our mission to promote a stigma-free understanding of lung cancer.



To find out more, please visit
lungconnectindia.org



CANCER INFORMATION NETWORK



癌症資訊網

—— 慈善基金 ——

Our organisation offers vital support for lung cancer patients by fostering community connections through peer support and professional advice on treatment options.

We empower patients by providing workshops, education, resources and awareness initiatives, helping them navigate their journey and build resilience together in a compassionate and understanding environment.

We also promote early screening like LDCT programmes, with the aim of improving survival rates,



Cancer Information Network offers advice and support for people in Hong Kong affected by all forms of cancer, with a strong focus on lung cancer.



For more information, please visit
our interactive information website
at cancerinformation.com.hk

Google Translate

RECORD LUNG CANCER INVESTMENT IN IRELAND



A groundbreaking €4.9 million lung cancer research programme, funded by the Irish Cancer Society, was launched in November 2024, marking the largest single investment in lung cancer in Ireland's history.

The pioneering initiative, led by the Beaumont RCSI Cancer Centre, aims to transform lung cancer care and research by bringing state-of-the-art cancer care to local communities and improving access to Irish Cancer Society support services.

Specifically, the new programme will focus on four key research projects:

- A clinical trial that invites high-risk individuals from North Dublin and the North East region to attend community-based lung health checks.
- Working with community-based doctors (GPs) to improve lung cancer detection, diagnostics and survivorship pathways.
- Evaluating a liquid biopsy to identify whether patients with newly diagnosed lung cancer may benefit from more tailored, personalised treatments.
- Testing immunotherapy treatments for KRAS-mutant lung cancers, which are particularly challenging to treat and common in Ireland.



Please click here for more information.

IMPROVING ACCESS AND RECRUITMENT TO CLINICAL TRIALS

Funded by the UK's Roy Castle Lung Cancer Foundation, the Lung I-ACT project aims to help lung cancer nurses discuss clinical trial options with patients

Led by Professor Catherine Henshall at Oxford Brookes University, researchers have collated data to inform the design of the Lung I-ACT tool – a patient leaflet designed to introduce clinical trials as a potential option. Patients can take it home, giving them time to absorb and

revisit the information at their own pace.

Now being piloted at seven NHS trusts across England and Scotland, the project will gather survey data and conduct interviews over the next six months. The goal is to assess whether the tool improves both the quality and frequency of conversations about lung cancer clinical trials.



Please click here for more information.



NEWS FROM LONGKANKER NEDERLAND

VIDEOS ABOUT STIGMA



Longkanker Nederland worked with a number of well-known Dutch people to create videos about the prejudices and stigma that surround lung cancer.

The videos were created following reports that Dutch radio and TV presenter Martijn Krabbé has been diagnosed with stage 4 lung cancer.



Please click here to view the videos.



You can also click here to read Longkanker Nederland's 2023 report about stigma.

Google Translate

MEREL HENNINK INTERVIEW



Merel Hennink, a member of Longkanker Nederland's patient panel and the organisation's GLCC representative, recently shared her insights on the importance of patient involvement in lung cancer research.

Her interview is featured on the **website of ZonMw**, a Dutch organisation dedicated to promoting quality and innovation in health research and healthcare.

In the interview, Merel speaks about her personal involvement in research and how it has benefitted her.

Google Translate

THE EVOLVING TOBACCO THREAT IN CANADA



As the Canadian Lung Association marks its 125th anniversary, CEO Sarah Butson has reflected on the evolving battle against tobacco.

In her article, *A century and a quarter reflection: The evolving tobacco threat*, she highlights key milestones in tobacco control, from early restrictions for minors in 1908 to Canada's global leadership in cigarette package warnings.

Despite progress, a new challenge looms – youth vaping. Sleek, flavoured devices have enticed a new generation into nicotine addiction, echoing past tobacco industry tactics. Canada now faces some of the highest youth vaping rates worldwide, demanding urgent action.

During National Non-Smoking Week in January, Butson called for stronger regulations and increased public health efforts to curb vaping's rise.



Please click here to read Sarah Butson's full article.

MAJOR RESEARCH GRANTS FROM LCRF

In November 2024, Lung Cancer Research Foundation of the US and the International Association for the Study of Lung Cancer (IASLC) awarded a \$2.5 million grant to support research focused on curing lung cancers caused by mutations in specific genes.



The project, titled 'Immune elimination of drug tolerant persister cells in oncogene-driven lung cancer', is led by David A. Barbie, Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.

This February, the LCRF also announced a new partnership with the Israel Cancer Research Fund.

As part of the collaboration, the organisations have awarded a grant of \$180,000 to fund a research study focused on targeting the IGFBP1 inhibitor as a potential treatment for lung and colorectal carcinomas.



Please [click here](#) to read about the November award.



Please [click here](#) to read about the February award.

SWEDISH MATERIALS TRANSLATED

Lungcancer Föreningen of Sweden has translated some of its key lung cancer information materials into different languages, including, Somali, Turkish, Arabic and Finnish.

These resources are available from the organisation's **information materials hub**.



PORTAL TO IMPROVE OUTCOMES

Campaign4Cancer of South Africa is set to launch an online platform called My Cancer Guide.

The overarching aim of the platform is to educate and empower people diagnosed with cancer and their families so they can improve their daily life and outcomes.

The platform provides access to the latest credible information on different types of cancer, treatment options and what to expect throughout the cancer experience.

By equipping patients and caregivers with reliable resources, My Cancer Guide aims to ensure they receive the best possible care and support, regardless of whether they are in the public or private healthcare system.



CANCER DATA BREAKTHROUGH IN SPAIN



AEACaP of Spain has helped to launch Más Datos Cáncer (More Cancer Data), the country's first open-access platform for cancer data.

The initiative has been created to promote equity in the approach to cancer throughout the country by improving access to

comprehensive, standardised and high-quality information.

Developed through the collaboration of 24 scientific organisations and patient associations, Más Datos Cáncer integrates knowledge into a structured model encompassing 69 key indicators.

These indicators are categorised into six critical stages of the cancer journey: health promotion and primary prevention, secondary prevention, early detection, diagnosis, healthcare, follow-up, and end-of-life care.



Please click here to find out more.



Visit Más Datos Cáncer at masdatoscancer.es

Google Translate

LUNGS: THE NEW BRAZILIAN HERO

In 2024, Oncoguia of Brazil launched a new lung cancer awareness campaign that celebrates the lungs as an 'invisible hero'.

The campaign aims to raise awareness about the importance of lung health and educate the public on how to reduce the risk of lung cancer.

Central to the initiative is a Hero Lung and other characters, which have been created to humanise the lung cancer journey and make it more relatable.

Across Brazil, various NGOs have partnered with the campaign, organising a wide range of online and offline activities to emphasise the



critical role of lung health and promote the message that the lungs are often an unsung hero in our bodies.



Please click here to find out more.

Google Translate

ENHANCING COMMUNICATION IN ARGENTINA

Between September and November 2024, Fundación Pacientes de Cáncer de Pulmón (FPCP) in Argentina conducted a survey of 100 participants to assess health literacy levels at the oncology service of Tornú Hospital in Buenos Aires.

This initiative provided valuable insights into patients' and caregivers' needs, not only in terms of demographics – such as where they live – but also their understanding of basic health issues.

By identifying gaps in knowledge, FPCP aims to enhance communication between patients, caregivers and healthcare professionals.

ILLUMINA NOVEMBRE'S 10TH ANNIVERSARY



ALCASE's Illumina Novembre campaign celebrated its 10th anniversary in November 2024.

The popular initiative sees landmarks, buildings and monuments across Italy being illuminated in white, the symbolic colour for lung cancer awareness.

The 2024 campaign was particularly significant as it involved a delegation of patients and caregivers from ALCASE being welcomed by the Italian Minister of Health. During this meeting, the group had the opportunity to present some of the most pressing challenges they face every day.



Please click here to find out more.

Google Translate

LUNG CANCER MEDIA ROUND-UP

UPDATED TNM STAGING SYSTEM SUCCESS

Researchers have found that the TNM-9 staging system for lung cancer offers better predictive power for limited-stage small cell lung cancer (LS-SCLC) than the eighth edition. LS-SCLC is a form of small cell lung cancer where the cancer is confined to one side of the chest. The ninth edition of the TNM staging system was launched in 2023



[Click here to find out more.](#)

TEST MAY BETTER PREDICT SURVIVAL IN EARLY STAGES

Researchers in the UK have developed a test called ORACLE that may be better at predicting lung cancer survival at the point of diagnosis than currently used clinical risk factors. The ORACLE test involves taking a tumour sample via biopsy, then analysing the tumour for the presence of a specific set of 23 genes. This type of test could help physicians make more informed decisions for people diagnosed with lung cancer and reduce the risk of cancer recurrence and metastasis.



[Click here to find out more.](#)



LUNG CANCER SCREENING MOVES AHEAD IN FRANCE

The French Society of Radiology (SFR) has announced the launch of a national lung cancer screening pilot study scheduled to begin during the second half of 2025. The research will involve 20,000 smokers or former smokers aged 50 to 74.



[Click here to find out more.](#)



LUNG CANCER LINKED TO POOR DIET

Researchers from the University of Florida in the US have published a paper that states glycogen, a form of sugar stored in the body for energy, can fuel lung cancer cells, helping them to grow and spread. As a result, the study suggests that eating a high-sugar, high fat diet may increase the risk of lung cancer or make it worse.



[Click here to find out more.](#)

REDUCING LUNG CANCER STIGMA

Researchers in the US have developed a training programme to help healthcare providers communicate effectively with lung cancer patients with a history of smoking without using stigmatising language. Developed at the Memorial Sloan Kettering Cancer Center in New York, the Empathic Communication Skills training is being tested at 16 healthcare sites in a randomised trial.



[Click here to read an interview with two of the programme's leads.](#)

WCLC 2024 HIGHLIGHTS

Click here to read the main news stories from the 2024 World Conference on Lung Cancer, which was held in San Diego in September.



[You can also view a highlights gallery from the conference by clicking here.](#)

EARLY DETECTION THROUGH URINE TEST

Scientists in Cambridge, UK, are creating a functional urine test that can detect some of the first signs of lung cancer.


The test, which identifies 'zombie' cells that can clear a path for cancers to emerge, is the first of its kind anywhere in the world.



[Click here to find out more.](#)

HOW TO... ASSESS YOUR SOCIAL MEDIA PRESENCE

With so many social platforms available, it can be overwhelming to know where to invest your time and resources.



But by assessing what's working on your channels and where improvements can be made, your organisation can ensure its efforts drive real engagement and results.

In this article, we explore the key questions to consider when reviewing your presence on major platforms, helping your team make informed decisions on where to focus for the greatest impact.



X (formerly Twitter)

X remains an important social media channel for many charities and not-for-profit organisations.

To make the best decisions about your presence on X, here are some key questions to consider:

- Are we clear on our objectives for using X? For example, do we want to use the channel to raise awareness of our organisation, fundraise, build our community, advocate for change?
- Are we effectively engaging with our followers? For example, responding to comments, retweeting, joining conversations.
- Are we maintaining a regular posting schedule and avoiding long gaps in activity?
- Which types of posts have performed best for us and why? For example, text-based posts, personal stories, images, videos.
- Are we seeing a return on investment for the time and resources spent on this platform?

Answering these key questions can your organisation assess whether its presence on X is achieving its intended impact and identify changes needed for future success.



TikTok

TikTok's rapid rise in popularity presents exciting opportunities for charities and not-for-profit organisations, especially those looking to connect with younger audiences.

With its dynamic, video-first format, the platform offers a powerful way to engage. But it also requires a dedicated investment of time and creativity.

Here are some key questions to consider:

- Do we have the skills and capacity to consistently create engaging video content?
- Does TikTok's audience align with our cause and mission?
- Are we making the most of TikTok's fundraising tools?



Instagram

Instagram's focus on visual storytelling makes it a powerful platform for charities and other organisations looking to showcase their mission through images and video.

With its diverse features and built-in donation tools, it's a great space to engage supporters and drive impact.

Here are some key questions to consider:

- Are we using a mix of stories, reels, and posts to connect with different audience segments?
- Are we making the most of Instagram's donation tools to support our fundraising goals?
- What visual stories resonate most with our audience and inspire action?

Take a fresh look at your feed. Are your posts telling compelling stories that resonate with your followers?

Showcasing your organisation's impact in an authentic and visually engaging way will keep your audience inspired and connected to your mission.

LinkedIn

LinkedIn can be a game-changer for organisations looking to connect with professionals, corporate sponsors, and volunteers.

As a professional networking platform, it calls for a strategic approach that differs from more casual social media channels.

Here are some key questions to help you make the most of LinkedIn:

- Is our target audience active on LinkedIn?
- Are we effectively engaging professionals and potential corporate sponsors?
- Are we using LinkedIn for thought leadership, networking and recruiting staff or volunteers?
- Do we tailor our content to resonate with a corporate audience, showcasing our impact and leadership?

LinkedIn is more than just a networking site. It's a powerful space to share insights, blogs, and updates that boost your credibility and showcase your expertise.



Make the most of it by creating content that highlights your impact and leadership. If your posts lean too heavily on general updates, consider shifting towards stories that resonate with corporate values, achievements and social impact.

Facebook

Despite a decline in younger users, Facebook remains a powerhouse for community-building and fundraising. For many organisations, it's still a key platform for connecting with supporters and driving impact.

Here are some key questions to consider:

- Are Facebook Groups and fundraising tools helping us build a strong community and boost donations?
- Are we happy with our engagement and performance metrics?
- Are we making the most of both organic and paid content to expand our reach?

A mix of organic content and paid campaigns can help you maximise reach and engagement. If you're focusing on one over the other, it might be time to shift your strategy and see how combining both approaches can drive even better results.

New platforms

With new platforms like Mastodon and BlueSky gaining momentum, charities and not-for-profit organisations have exciting opportunities to engage with niche audiences in fresh, innovative ways.

Here are some key questions to explore:

- Should we experiment with emerging platforms to connect with specialized communities?
- Can we allocate resources to build a presence and make an impact on these platforms?
- Should we consider decentralised and privacy-conscious messaging platforms – like those using Blockchain technology – as an alternative to traditional social media?

As data privacy becomes an increasingly important issue, many audiences are flocking to decentralised platforms. As we are all passionate about privacy or ethics, this could be an opportunity to connect with like-minded individuals and expand your reach!

That said, building a following on new platforms takes time and effort, so it's important to ensure you have the resources in place before beginning a strategy centred around emerging spaces.

By carefully assessing your capacity, you can make a smart, impactful decision that aligns with your mission and audience needs.



Fundación Pacientes de Cáncer de Pulmón: www.fundacionpcp.org



LungFoundation Australia:
www.lungfoundation.com.au



Oncoguia Institute: www.oncoguia.org.br



Bulgarian Anti-Cancer Patient Association (APOZ): www.oncobg.info



Canadian Lung Association:
www.lung.ca

Lung Cancer Canada:
www.lungcancercanada.ca

The Lung Health Foundation:
www.lunghealth.ca



OnkoMaják
www.onkomajak.cz



Patientforeningen Lungekraeft:
www.lungekraeft.dk



La Ligue Contre le Cancer:
www.ligue-cancer.net



Deutsche Krebsgesellschaft E.V:
www.krebsgesellschaft.de



FairLife Lung Cancer Care
fairlifelcc.com



Cancer Information Network
cancerinformation.com.hk



Lélek-Zet: lelekzetegyesulet.hu



Lung Connect India Foundation
lungconnectindia.org



Irish Cancer Society: www.cancer.ie



The Israeli Lung Cancer Foundation:
www.ilcf.org.il



ALCASE Italia: www.alcase.eu

Cittadinanzattiva: www.cittadinanzattiva.it



Women Against Lung Cancer in Europe:
www.womenagainstlungcancer.eu



Cancer Net Japan: www.cancernet.jp

West Japan Oncology Group (WJOG):
www.wjog.jp



Frente Unido por el Cáncer de Pulmón:
frentepulmon.org

Respirando Con Valor A.C:
www.respirandoconvalor.org



Longkanker Nederland:
www.longkankernederland.nl



LungeKreft Foreningen:
www.lungekreftforeningen.no



Esperantra: www.esperantra.org



Associação Portuguesa de Luta Contra o Cancro do Pulmão:
www.pulmonale.pt



Na-Vdih (Inspire):
www.na-vdih.si



Campaigning for Cancer
campaign4cancer.co.za/wp



Asociación Española De Afectados De Cancer De Pulmón:
www.afectadoscancerdepulmon.com

La Asociación Española Contra el Cáncer: www.aecc.es



Lungcancerforeningen:
www.lungcancerforeningen.se



Forum Lungenkrebs:
www.facebook.com



Formosa Cancer Foundation
canceraway.org.tw



Pembe Hanim: www.pembehanim.com.tr



Asthma + Lung UK:
www.asthmaandlung.org.uk

Lung Cancer Nursing UK:
www.lcnuk.org

Roy Castle Lung Cancer Foundation:
www.roycastle.org



CancerCare: www.cancercare.org

GO2 for Lung Cancer:
www.go2.org

Lung Cancer Research Foundation:
www.lungcancerresearchfoundation.org

Prevent Cancer Foundation:
www.preventcancer.org

In 2025, the GLCC acknowledges the support of its sustaining partners:

Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead, Iovance Biotherapeutics, Johnson & Johnson, Merck, Novartis, Pfizer, Regeneron, Roche, and Takeda.

The GLCC has prepared the content of this newsletter responsibly and carefully, but disclaims all warranties, expressed and implied, with respect to any product identified in this newsletter and bears no responsibility for the accuracy, content or legality of any website quoted in the newsletter or for that of any subsequent links. This disclaimer shall be governed by and construed in accordance with English Law under the exclusive jurisdiction of the English courts.

Editorial support: Need A Writer www.needawriter.uk Design: Hornett Design www.hornettdesign.co.uk



GLOBAL LUNG CANCER
COALITION

